ANDOVER, Mass. and HAIFA, Israel, March 11, 2026 /PRNewswire/ — MeMed, a leader in advanced host-response diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to MeMed BV Flex™, a test designed to accurately distinguish between bacterial and viral infections based on the body’s immune response.
View offers 2D and 3D visualisation, along with AI-based tools, to assist in clinical decision making.
OncoPatch announced today that it received FDA 510(k) for its Oncopatch Surface brachytherapy system for treating localized tumors.
MiniMed (Nasdaq:MMED) announced that it received CE mark for the use of its MiniMed 780G with the Instinct sensor made by Abbott.
ReVision Implant announced today that it received FDA breakthrough device designation for its Occular visual cortical prosthesis.
LifeVac is approved for use as a single-use, non-powered, non-invasive airway clearance device.
Philips (NYSE: PHG)+ announced today that it received FDA 510(k) clearance for its SmartHeart planning solution.
The FDA’s expanded clearances broaden the application of Bayer’s Medrad MRXperion system across a wider range of MR settings.
BD (NYSE: BDX)+ announced today that it received CE mark approval for its Revello vascular covered stent system.
LOS ALTOS, Calif., March 4, 2026 /PRNewswire/ — XYRA LLC announces that the US Patent and Trademark Office (USPTO) has issued a patent (No. 12,551,706) protecting the use of dose adjusted budiodarone for the treatment of atrial fibrillation (AF), with monitoring to correspondingly reduce or delay the risk of stroke and/or congestive heart failure.